BUSINESSFORTUNE
Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies
Insilico Medicine and SK Biopharmaceuticals signed a $2.5B partnership to develop neuroimmune therapies using AI-driven drug discovery. Insilico will design candidates via its Pharma.AI platform, while SK Biopharmaceuticals handles late-stage development and commercialization. The deal includes potential milestone payments and royalties, marking Insilico's largest Asia-Pacific collaboration.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
- China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn
- Incyte strikes up to $2bn deal for blood disorder biotech
- Roche is striking a $2.3 billion deal with Nurix Therapeutics to develop a blood cancer drug
- China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
- China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials